Drug selection for anaplastic lymphoma kinase-positive non-small-cell lung cancer
Mené aux Etats-Unis et en Espagne sur 137 patients atteints d'un cancer de stade avancé ou réfractaire et notamment d'un cancer du poumon non à petites cellules présentant un réarrangement ALK, cet essai de phase I/II évalue la dose maximale tolérée puis l'efficacité, du point de vue du taux de réponse objective, et la toxicité du brigatinib
Over the last few years, major therapeutic advances have occurred in the anaplastic lymphoma kinase (ALK)-rearranged subtype of non-small-cell lung cancer (NSCLC), commencing with the finding that the targeted therapy crizotinib provides better clinical benefit than does chemotherapy.1 Almost all patients given crizotinib eventually develop disease progression, with the brain being a common site of metastasis. Both ALK pathway-dependent and ALK pathway-independent mechanisms of resistance to crizotinib have been identified.
The Lancet Oncology , commentaire, 2015